Tirzepatide, a newer diabetes drug, has been shown to reduce patient hemoglobin A1c levels, as well as lowering body weight and improving insulin sensitivity markers in patients with type 2 diabetes. Read more
Some drugs used to lower glucose in patients with diabetes, such as metformin, SGLT2 inhibitors, and sulfonylureas, might have beneficial effects on COVID-19, potentially affecting the risk of progression to severe disease and death. Read more
SGLT-2 inhibitors like sotagliflozin are antihyperglycemic agents approved in the US for use in patients with type 2 diabetes. However, sotagliflozin is also approved for type 1 diabetes in Europe, and studies have shown that using sotagliflozin along with insulin has benefits in patients with type 1 diabetes. Read more
People who have type 2 diabetes are likely to have complicated medication regimens that involve taking multiple drugs (also known as polypharmacy). Complex medication regimens are associated with worse health outcomes, as it is more difficult to follow a complicated treatment correctly, and there is increased risk for drug interactions. Read more
GIP and GLP-1 are substances produced in the body’s digestive tract, and they play important roles in regulating body weight and food intake. A recently published study on their effects suggests that they may one day be used to develop drugs to treat obesity and type 2 diabetes. Read more
A clinical trial is being conducted in the United Kingdom to investigate whether the diabetes drug exenatide (Byetta) can be used to treat Parkinson’s Disease. Previous research has found that the risk for Parkinson’s is reduced in people who are treated with exenatide for their type 2 diabetes. Read more
Metformin, a commonly-prescribed diabetes drug, may have other benefits, researchers say. A study found that metformin use in patients with type 2 diabetes is associated with a reduced risk of rehospitalization and death following surgery. Read more
Metformin is the typical first-line treatment for people with type 2 diabetes, but the ADA suggests early combination therapy with other medications should be used in patients with type 2 diabetes and chronic kidney disease or cardiovascular disease. Read more
Studies of diabetes drugs empagliflozin and dapagliflozin, both in the SGLT-2 inhibitor class, have shown they help reduce cardiovascular risk for diabetes patients. Now, researchers have found that empagliflozin is beneficial for the heart in people without diabetes as well. Read more
The diabetes drug semaglutide, administered once-weekly subcutaneously and used in conjunction with lifestyle modifications, helped people with overweight or obesity achieve sustained, significant reductions in body weight. Read more
Eli Lilly is expanding its existing type 1 diabetes partnership with Life for a Child, with the goal of supporting more than six times as many children in the next 10 years. Lilly plans to expand care to 150,000 young people with diabetes over the next decade, providing free medicine and equipment like reusable pens […]
Insulin is the mainstay treatment for patients with type 2 diabetes who also have beta-cell failure; however, some insulin regimens can be complicated to manage and may increase the risk of hypoglycemia. Now, researchers say that a simple add-on therapy with the GLP-1 Agonist medication albiglutide can reduce insulin use for patients with type 2 […]
High blood glucose levels can damage the heart’s nerves and blood vessels. This contributes to the development of heart diseases and eventual heart attacks. However, new research shows that starting patients on medication to prevent cardiovascular diseases when they are first diagnosed with diabetes can help reduce the risk. Read more
New studies have investigated a once-daily pill that can optimize insulin therapy and reduce HbA1c among adults with type 1 diabetes. The pill, a novel liver-selective glucokinase activator, also known as TTP399, showed superior A1c reduction compared to placebo. Read more
A recent study that aimed to review and assess all the current evidence regarding SGLT2 inhibitors and their impact on death from all causes in diabetes patients found that overall, this class of diabetes drug was associated with a reduction in all-cause mortality. Read more
Empagliflozin (sold under the brand name Jardiance) may reduce major adverse kidney events in some type 2 diabetes patients better than other medications, researchers say. The study used U.S. Department of Veterans Affairs (VA) data to assess the effectiveness of empagliflozin versus other antihyperglycemic drugs. Read more
Golimumab is a human antibody that is used as an immunosuppressive drug (brand name Simponi) and is approved for the treatment of several autoimmune conditions, including ulcerative colitis. Researchers investigated whether golimumab could preserve beta-cell function in young people newly diagnosed with type 1 diabetes. Read more
Some research has suggested that inhibiting the protein DPP-4, which is produced by the human body, could provide benefit to patients infected with COVID-19. Sitagliptin is a diabetes drug in the DPP-4 inhibitor class that has also shown anti-inflammatory and immunoregulatory effects. Researchers investigated whether sitagliptin could help treat hospitalized COVID patients with type 2 […]
Metformin is the standard first medication treatment of choice for people newly diagnosed with type 2 diabetes. A group of researchers decided to examine whether metformin, which this year celebrates its 63rd anniversary as a type 2 diabetes treatment, continues to earn its spot as a key member of the diabetes medication “All-Star Team.” Read more
Many older patients with type 2 diabetes deal with polypharmacy — taking multiple medications for their diabetes and other conditions. Polypharmacy can be burdensome in various ways, including multiple side effects of the various medications. Researchers investigated whether the use of polypharmacy put elderly patients at increased risk for hospitalization, falls, and death from all […]
